For the quarter ending 2026-03-31, TCRT had -$1,031K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,006 | -893 | -1,159 | -2,124 |
| Depreciation | 8 | 7 | 0 | 0 |
| Change in fair value of warrant liability | - | 0 | 0 | 31 |
| Common stock issued for services rendered | 85 | 208 | 174 | - |
| Stock-based compensation | 56 | 35 | 127 | 252 |
| Receivables | -3 | 3 | -2 | -3 |
| Prepaid expenses and other current assets | -40 | -202 | -166 | 18 |
| Accounts payable | -212 | -230 | 34 | 293 |
| Accrued expenses | -5 | 122 | -188 | 90 |
| Net cash flows from operating activities | -1,031 | -552 | -844 | -1,473 |
| Purchases of property and equipment | - | 1 | 97 | - |
| Net cash flows from investing activities | - | -1 | -97 | - |
| Proceeds from the issuance of common stock and pre funded warrants, net of offering costs | - | 0 | 0 | 1,911 |
| Proceeds from sale of series a-1 preferred stock | - | 0 | 0 | 500 |
| Proceeds from sale of series a-2 preferred stock | - | 0 | 0 | 850 |
| Net cash flows from financing activities | - | 0 | 0 | 3,261 |
| Net decrease in cash, cash equivalents | -1,031 | -553 | -941 | 1,788 |
| Cash and cash equivalents, beginning of period | 1,385 | 1,938 | 1,091 | - |
| Cash and cash equivalents, end of period | 354 | 1,385 | 1,938 | - |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)